86C.F BIOTALYS NV
- Market cap
- EUR 87.4M
- P/E
- -
- P/B
- 6.07x
- ROE
- -130.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 86C.F undervalued?
Graham numberThe Graham number of BIOTALYS NV cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOTALYS NV fundamental analysis
No fundamental analysis for BIOTALYS NV yet.
BIOTALYS NV stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOTALYS NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; B…
Full company profileBIOTALYS NV financial statements
BIOTALYS NV annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.1M | -22.5M | -20.9M | -13.5M | -15.8M |
| EBITDA | - | -20.9M | -18.5M | -11.2M | -13.9M |
| Net Income | -16.9M | -22.7M | -20.5M | -13.2M | -15.8M |
| EPS | -0.55 | -0.73 | -0.64 | -0.35 | -0.42 |
| Balance Sheet | |||||
| Total Assets | 70.3M | 49.5M | 36.6M | 36.7M | 19.7M |
| Total Liabilities | 11.4M | 11.4M | 11.0M | 9.14M | 7.63M |
| Shareholders' Equity | 58.9M | 38.1M | 25.6M | 27.6M | 12.1M |
| Cash & Short-term Investments | 56.1M | 34.1M | 21.6M | 22.6M | 8.04M |
| Cash Flow | |||||
| Operating Cash Flow | -16.8M | -20.1M | -18.3M | -12.7M | -13.7M |
| Capital Expenditure | 1.33M | 707K | 455K | 138K | 182K |
| Free Cash Flow | -18.1M | -20.8M | -18.7M | -12.8M | -13.9M |
| Ratios | |||||
| ROE | -28.7% | -59.6% | -80.2% | -47.8% | -130.2% |
| ROA | -24.1% | -45.9% | -56.1% | -35.9% | -79.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
BIOTALYS NV dividends
BIOTALYS NV has not paid dividends in the last 5 fiscal years.
Who owns BIOTALYS NV
- Insiders 27.44%
- Institutions 17.69%
- Public & others 54.87%
- Shares outstanding 45.4M
- Free float 25.6M
BIOTALYS NV company profile
- Company name
- BIOTALYS NV
- Ticker
- 86C.F
- ISIN
- BE0974386188
- Exchange
- Frankfurt Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 37
- Fiscal year end
- December
- Address
- Buchtenstraat 11, Ghent, Belgium, 9051
- Phone
- 32 9 274 54 00
- Website
- biotalys.com
About BIOTALYS NV
Biotalys NV, an agricultural technology company, discovers and develops protein-based biocontrol solutions in Belgium and internationally. The company offers biofungicides and bioinsecticides. It also provides the AGROBODY Foundry technology platform, which generates protein-based crop protection products. In addition, the company develops EVOCA 1st generation, EVOCA Next generation, and BIOFUN-6 targeting botrytis, powdery mildew, and other fungi in fruits and vegetables; BIOFUN-7 targeting leafspot disease in cowpeas and other legumes; BIOFUN-4 targeting oomycetes in fruits and vegetables; BIOFUN-8 targeting altenaria in fruits, vegetables, and specialty crops; and BioIns-2 targeting key insect pests. The company was formerly known as Agrosavfe NV and changed its name to Biotalys NV in December 2019. Biotalys NV was incorporated in 2013 and is headquartered in Ghent, Belgium.
BIOTALYS NV management
3- Dr. Carlo BouttonCEO & Chief Scientific Officer
- Mr. Luc Van FraeyenhovenChief Financial Officer
- Toon MusschootHead of Investor Relations & Communication